Real‐world outcomes of 18,186 metastatic solid tumor outpatients: Baseline blood cell counts correlate with survival after immune checkpoint inhibitor therapy

Real‐world outcomes of 18,186 metastatic solid tumor outpatients: Baseline blood cell counts correlate with survival after immune checkpoint inhibitor therapy

Abstract Background Patient survival in advanced/metastatic melanoma, non‐small cell lung cancer (NSCLC), and renal cell carcinoma (RCC) has improved with immune checkpoint inhibitors (ICI). Biomarkers' role in prognosis and treatment has been limited by conflicting trial results. Methods This...

Full description

Bibliographic Details
Main Authors: Jerome H. Goldschmidt, Lin‐Na Chou, Philip K. Chan, Liwei Chen, Nicholas Robert, Joyce Kinsey, Katherine Pitts, Matt Nestor, Edwin P. Rock, Hillard M. Lazarus
Format: Article
Language:English
Published: Wiley 2023-11-01
Series:Cancer Medicine
Subjects:
biomarkers
check point control
medical oncology
melanoma
non small cell lung cancer
renal cancer
Online Access:https://doi.org/10.1002/cam4.6645

Internet

https://doi.org/10.1002/cam4.6645

Similar Items